Skip to content

Patient experience and advocacy

TL;DR — Neuropathic pain reshapes sleep, mobility, work, relationships and trust in care. In a 70-person painful-diabetic-neuropathy qualitative study, themes spanned physical function, daily life, social/psychological effects and sleep (Brod 2015, PMID 25354872). A 10-person zoster/PHN study found daily living affected in 9, emotional and physical function in 8, and sleep in 7 (Belizan 2024, PMID 39232368). These are thematic samples, not prevalence estimates.

Language and legitimacy

Descriptors help communication but do not prove diagnosis. Dismissal and over-certainty are both harmful: acknowledge symptoms while grading evidence explicitly.

Patient-centered interviews across diabetic neuropathy and PHN found both shared and syndrome-specific language: burning and soreness were common to both, numbness/tingling predominated in diabetic neuropathy, and itch/hypersensitivity in PHN (Hwang 2018, PMID 29656511). The point is not to turn words into a diagnostic test; it is to ensure measures include the symptoms patients actually report.

Communication failure Consequence Better research/clinical control
“Your scan is normal” as dismissal Erodes trust; ignores small-fiber or central lesions State what the test assessed and did not assess
Descriptor treated as proof Misclassification and missed alternatives Pair symptoms with lesion evidence and signs
Pain score as sole outcome Sleep, touch, gait and role effects disappear Use multidomain patient-reported outcomes
Benefit discussed without responder probability Inflated expectations Give absolute responder and withdrawal rates
Dose reduction framed as failure Under-reporting of toxicity Shared cancer-control/neurologic-risk discussion

Sleep

Falling asleep, nocturnal waking and non-restorative sleep were prominent in painful diabetic neuropathy interviews (Brod 2015, PMID 25354872). Sedating treatment can improve sleep or worsen daytime function.

In 30 interviews conducted in the United States and Japan, sleep disturbance was reported in both diabetic neuropathy and PHN; diabetic participants also emphasized walking and stairs, while PHN participants emphasized avoiding physical contact and emotional distress (Hwang 2018, PMID 29656511). Cross-country thematic similarity does not establish cultural universality because only two countries and 30 participants were sampled.

Mobility and safety

Pain plus sensory loss affects walking, balance, footwear and falls. Pain relief does not restore protective sensation.

Work and roles

Concentration, productivity, chores and recreation were affected in the qualitative diabetic study (Brod 2015, PMID 25354872). Outcomes should measure participation, not pain alone.

In a six-country treated cohort, 35% of 140 people with painful diabetic neuropathy reported employment disruption despite 91% using prescription treatment (Tölle 2006, PMID 16389164). In 103 people with SCI neuropathic pain, only 13.6% were employed; among those employed, overall work impairment was 38%, and annualized direct plus indirect cost was US$26,270 in the study's price context (Mann 2013, PMID 23588572). Neither convenience sample supports a national burden estimate without sampling weights.

Treatment burden

Serial trials produce dizziness, edema, cognitive slowing, withdrawal and cost while only minorities respond (Finnerup 2015, PMID 25575710). Device pathways add procedures and revisions.

Treatment burden includes titration, repeated appointments, driving restrictions, tapering, out-of-pocket cost and the emotional work of deciding whether partial relief offsets cognitive or balance effects. Trials commonly report adverse events by drug but do not integrate these time and participation costs into net benefit.

Communication

Explain lesion certainty, mixed mechanisms, expected responder probability, time-limited trials and stopping rules. “Nothing on the scan” is not evidence that symptoms are imaginary.

CIPN studies show a particularly consequential information problem. Fifteen survivor interviews identified difficulty processing CIPN information, reliance on trust during treatment decisions, barriers to reporting and challenges managing symptoms (Tanay 2019, PMID 30790382). A synthesis of five studies/88 participants described CIPN as unclear, deprioritized beside cancer and then persistent into survivorship (Tanay 2017, PMID 26786536).

Risk communication should therefore occur before neurotoxic treatment, be repeated during therapy, distinguish reversible acute sensations from cumulative injury, and make reporting thresholds explicit. This is an inference from qualitative evidence, not a tested communication intervention.

What should be measured

A review found 12 neuropathy patient-reported-outcome studies: two sleep, five painful-symptom and five quality-of-life measures, ranging from 1 to 97 items and 1 to 18 domains (Bredfeldt 2015, PMID 26385309). Internal consistency was adequate, but domain overlap and comparator standardization were limited.

The 18-item DPNPI retained physical function/mobility, sleep and daily-activity domains; internal consistency was 0.91–0.96 and test–retest reliability 0.84–0.91 in a 124-person validation sample (Brod 2015, PMID 26068732). Reliability does not establish responsiveness or a universal meaningful-change threshold.

Outcome layer Example Reporting requirement
Symptom Burning, numbness, touch-evoked pain Severity plus frequency/distribution
Function Walking, hand use, stairs Baseline ability and meaningful-change threshold
Sleep Initiation, maintenance, restoration Separate analgesia from drug sedation
Participation Work, caregiving, social contact Days/roles affected, not generic QoL alone
Safety Falls, ulcers, medication errors Prospective ascertainment
Treatment burden Visits, titration, procedures, cost Patient time and discontinuation reason
Global value Patient global impression Pair with objective harms and attrition

Advocacy priorities

Access to neurologic assessment, pain rehabilitation, vaccination, foot protection, cancer survivorship care and research participation differ by system.

Advocacy should not collapse into drug access alone. Priorities include timely etiologic diagnosis; equitable access to rehabilitation and foot care; plain-language risk communication; inclusion of older adults, renal impairment and multimorbidity in trials; and outcomes chosen with patient partners.

Evidence limits in patient voice

Qualitative saturation establishes thematic coverage within a sample, not frequency in a population. English-language and clinic-based samples overrepresent people who reach specialist care; digital recruitment can exclude people with limited connectivity. Diagnosis-specific evidence should not be generalized to all neuropathic syndromes without showing what transfers and what does not.

Ethics table

Principle Implementation
Public sources No private-group harvesting
Aggregate themes No identifying details
Short quotations ≤15 words, attributed
Coverage honesty State language/geography bias
Co-production Patient partners shape outcomes

Evidence interpretation map

The table makes the evidence role and inferential boundary explicit; it is not a replacement for the full reports.

PMID Year Evidence role What it cannot establish alone
25354872 2015 Painful-diabetic-neuropathy qualitative burden Theme prevalence
29656511 2018 US/Japan DPN and PHN concept elicitation Cultural universality
26385309 2015 Patient-reported-measure review A single gold-standard instrument
26068732 2015 DPNPI development/validation Responsiveness in every syndrome
30790382 2019 CIPN survivor interviews Population frequency of support needs
23588572 2013 SCI neuropathic-pain burden survey National causal economic estimate

Minimum reporting controls

Domain Required report
Case definition Possible, probable or definite neuropathic pain
Etiology Lesion/disease and diagnostic evidence
Distribution Focal, length-dependent, dermatomal, at-level or below-level
Baseline phenotype Negative and positive sensory signs
Comparator Placebo/sham, active care or natural history
Exposure Dose, duration, adherence and co-interventions
Benefit Mean change plus ≥30% and ≥50% responders where applicable
Function Sleep, mobility, participation and patient global change
Harm Adverse events, withdrawals and serious events
Durability Follow-up after treatment and attrition
Subgroups Prespecified interaction test, not within-group significance
Missingness Denominator and imputation method

Reporting cautions

  • Do not infer lesion presence from a symptom descriptor.
  • Do not convert a group-average association into an individual diagnostic rule.
  • Do not treat statistical significance as clinically important benefit.
  • Do not compare NNTs without checking outcome threshold, duration and population.
  • Do not interpret an inactive or completed registry record as proof of efficacy.
  • Do not merge painful and painless neuropathy outcomes.
  • Do not omit adverse-event withdrawals from responder interpretation.
  • Do not call a post hoc subgroup predictive without an interaction test.
  • Do not generalize a focal peripheral result to central neuropathic pain.
  • State when evidence is short-term, indirect or restricted to a selected cohort.

Open questions

  • Which outcomes do patients weight most?
  • Does diagnostic explanation improve function?
  • How can medication burden be measured?
  • Which access disparities drive preventable disability?

References

  1. Brod M, Pohlman B, Blum SI, et al.. Burden of Illness of Diabetic Peripheral Neuropathic Pain: A Qualitative Study. Patient. 2015;8:339-48. PMID 25354872
  2. Belizan M, Augustovski F, Bardach A, et al.. Patient Experience of Herpes Zoster Disease in Argentina: Validation of a Health-Related Quality of Life Conceptual Model. Value Health Reg Issues. 2024;44:101044. PMID 39232368
  3. Doth AH, Hansson PT, Jensen MP, et al.. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010;149:338-344. PMID 20227832
  4. Finnerup NB, Attal N, Haroutounian S, et al.. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-73. PMID 25575710
  5. Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021;397:2082-2097. PMID 34062143
  6. Tomás CC, Oliveira E, Sousa D, et al.. Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016. BMC Health Serv Res. 2016;16 Suppl 3:200. PMID 27409075
  7. Ushida T. [Chronic Pain: Definition/Conception/Classification of Pain]. Brain Nerve. 2023;75:201-205. PMID 36890755
  8. Schroeck JL, Ford J, Conway EL, et al.. Review of Safety and Efficacy of Sleep Medicines in Older Adults. Clin Ther. 2016;38:2340-2372. PMID 27751669
  9. Zilliox LA. Neuropathic Pain. Continuum (Minneap Minn). 2017;23:512-532. PMID 28375916
  10. Bäckryd E, Ghafouri N, Gerdle B, et al.. Rehabilitation interventions for neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. J Rehabil Med. 2024;56:jrm40188. PMID 39101676
  11. Zhang YH, Hu HY, Xiong YC, et al.. Exercise for Neuropathic Pain: A Systematic Review and Expert Consensus. Front Med (Lausanne). 2021;8:756940. PMID 34901069
  12. Derry S, Bell RF, Straube S, et al.. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076. PMID 30673120
  13. Wiffen PJ, Derry S, Bell RF, et al.. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938. PMID 28597471
  14. Busse JW, Wang L, Kamaleldin M, et al.. Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. JAMA. 2018;320:2448-2460. PMID 30561481
  15. Mücke M, Phillips T, Radbruch L, et al.. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:CD012182. PMID 29513392
  16. Seretny M, Currie GL, Sena ES, et al.. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155:2461-2470. PMID 25261162
  17. Burke D, Fullen BM, Stokes D, et al.. Neuropathic pain prevalence following spinal cord injury: A systematic review and meta-analysis. Eur J Pain. 2017;21:29-44. PMID 27341614
  18. Haroutiunian S, Nikolajsen L, Finnerup NB, et al.. The neuropathic component in persistent postsurgical pain: a systematic literature review. Pain. 2013;154:95-102. PMID 23273105
  19. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833. PMID 24916088
  20. Saguil A, Kane S, Mercado M, et al.. Herpes Zoster and Postherpetic Neuralgia: Prevention and Management. Am Fam Physician. 2017;96:656-663. PMID 29431387
  21. Farquhar-Smith P. Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care. 2011;5:1-7. PMID 21192267
  22. Rosenberger DC, Blechschmidt V, Timmerman H, et al.. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm (Vienna). 2020;127:589-624. PMID 32036431
  23. Rosenberger DC, Pogatzki-Zahn EM. Chronic post-surgical pain - update on incidence, risk factors and preventive treatment options. BJA Educ. 2022;22:190-196. PMID 35496645
  24. Attal N, Bouhassira D, Colvin L. Advances and challenges in neuropathic pain: a narrative review and future directions. Br J Anaesth. 2023;131:79-92. PMID 37210279
  25. Colloca L, Ludman T, Bouhassira D, et al.. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. PMID 28205574
  26. Hwang S, van Nooten F, Wells T, et al. Neuropathic pain: A patient-centred approach to measuring outcomes. Health Expect. 2018;21:774-786. PMID 29656511
  27. Bredfeldt C, Altschuler A, Adams AS, et al. Patient reported outcomes for diabetic peripheral neuropathy. J Diabetes Complications. 2015;29:1112-1118. PMID 26385309
  28. Brod M, Blum SI, Bushnell DM, et al. Development and validation of the Diabetic Peripheral Neuropathic Pain Impact (DPNPI) measure, a patient-reported outcome measure. Qual Life Res. 2015;24:3001-3014. PMID 26068732
  29. Mann R, Schaefer C, Sadosky A, et al. Burden of spinal cord injury-related neuropathic pain in the United States: retrospective chart review and cross-sectional survey. Spinal Cord. 2013;51:564-570. PMID 23588572
  30. Tanay MA, Armes J. Lived experiences and support needs of women who developed chemotherapy-induced peripheral neuropathy following treatment for breast and ovarian cancer. Eur J Cancer Care (Engl). 2019;28:e13011. PMID 30790382
  31. Tanay MAL, Armes J, Ream E. The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care (Engl). 2017;26. PMID 26786536
  32. Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications. 2006;20:26-33. PMID 16389164